The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA‐Approved Drugs
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70064 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Samantha Lynn Bailey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, US…. Hauptthemen laut MEDLINE: Drug Labeling. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.
Abstract (Originalsprache)
A critical aspect of drug development is evaluating pharmacokinetics (PK) and pharmacodynamics to assess how intrinsic (e.g., age, sex, comorbidities, and genomics) and extrinsic (e.g., drug–drug interactions [DDIs] and food interaction) factors influence drug exposure and response. These aspects guide dose selection and inform drug labeling by accounting for interindividual variability to ensure safe and effective use across complex patient populations. However, identifying the relationship of co‐occurring factors, resembling complex patient populations, remains challenging. Herein, we analyzed drug labeling for therapeutic products approved by the Center of Drug Evaluation and Research at the US Food and Drug Administration from 2019 to 2023 to understand if intrinsic and extrinsic factors are considered simultaneously and how these factors influence prescribing recommendations. We characterized factors including pharmacogenomics (PGx), renal and hepatic function, age, pregnancy, body weight, comorbidities, and DDIs. Among 227 drug labelings, 93% independently assessed more than one factor and 2.6% evaluated the combined influence of two factors. Most drug labelings focused on single factors, with PK DDIs (70.0%), renal impairment (74.4%), and age (78.9%) frequently assessed. In rare disease indications, no significant differences in factor assessment frequency were observed. Of the six drug labelings that address simultaneously occurring factors, four addressed the interaction between PGx and PK DDIs. This analysis highlights a gap in evaluating co‐occurring intrinsic and extrinsic factors in drug labeling, underscoring the need for integrated approaches during drug development to better guide clinical decision making for complex patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
- Center for Drug Evaluation and Research, Office of Translational Science, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USA.
ORCID-Profile: Samantha Lynn Bailey, Sydney Stern
Förderung
- Intramural FDA HHS
Zitieren
APA
Bailey, S. L., Stern, S., Dahmane, E., Ramamoorthy, A., Pacanowski, M., & Schuck, R. (2025). The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA‐Approved Drugs. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70064
Vancouver
Bailey SL, Stern S, Dahmane E, Ramamoorthy A, Pacanowski M, Schuck R. The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA‐Approved Drugs. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70064
BibTeX
@article{Bailey2025,
author = {Bailey, Samantha Lynn and Stern, Sydney and Dahmane, Elyes and Ramamoorthy, Anuradha and Pacanowski, Michael and Schuck, Robert},
title = {The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA‐Approved Drugs},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70064}
}
EUVIMED